Substance Use Disorder Long Acting Medication

{
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1143" ]
    }, {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1144" ]
    }, {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1147" ]
    } ]
  },
  "date" : "2021-11-02T01:01:56-04:00",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2021-11-02T01:01:56.000-04:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "NCQA PHEMUR",
  "jurisdiction" : [ {
    "extension" : [ {
      "valueString" : "UNKNOWN",
      "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason"
    } ]
  } ],
  "purpose" : "(Clinical Focus: The purpose of this Grouping value set is to represent concepts for long acting substance use disorder medications.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent generic, human use and prescribable buprenorphine implant, buprenorphine injection and naltrexone injection medications.),(Exclusion Criteria: Excludes concepts that represent non-prescribable or branded drugs and excludes concepts that represent components or ingredients. Excludes short acting oral and sublingual medications.)",
  "name" : "SubstanceUseDisorderLongActingMedication",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1655032",
      "display" : "1 ML buprenorphine 0.3 MG/ML Cartridge",
      "version" : "06052023"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1797650",
      "display" : "buprenorphine 74.2 MG Drug Implant",
      "version" : "06052023"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1996184",
      "display" : "0.5 ML buprenorphine 200 MG/ML Prefilled Syringe",
      "version" : "06052023"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1996192",
      "display" : "1.5 ML buprenorphine 200 MG/ML Prefilled Syringe",
      "version" : "06052023"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "238129",
      "display" : "1 ML buprenorphine 0.3 MG/ML Injection",
      "version" : "06052023"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "637213",
      "display" : "naltrexone 380 MG Injection",
      "version" : "06052023"
    } ],
    "offset" : 0,
    "total" : 6,
    "identifier" : "urn:uuid:9d41f5c2-2bdf-4387-981d-21d0a36d33d6",
    "timestamp" : "2023-06-29T20:06:04-04:00",
    "parameter" : [ {
      "name" : "count",
      "valueInteger" : 1000
    }, {
      "name" : "offset",
      "valueInteger" : 0
    } ]
  },
  "title" : "Substance Use Disorder Long Acting Medication",
  "extension" : [ {
    "valueString" : "NCQA PHEMUR Author",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueDate" : "2022-12-15",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2021-11-02",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "active",
  "id" : "c15afb0d-43e4-4659-a56b-ab449377a6e3",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1149",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.464.1003.1149"
  } ],
  "version" : "20211102"
}